How would you manage a premenopausal woman with DCIS who has a contraindication to tamoxifen?

Given the modest benefits of adjuvant and/or risk reduction endocrine therapy in patients with ER+ DCIS, in terms of reducing the risk of an ipsilateral in-breast recurrence following surgery and radiation and reducing the risk of a contralateral estrogen receptor-positive breast cancer, and the abs...